In addition, in this study, amongst patients that received rituximab maintenance, those that are KIR3DL1+/Bw4+ showed significantly improved TTRF, duration of response and tumor shrinkage than for those not KIR3DL1+/Bw4+. Here, KIR3DL1 is linked to neoplasm.